Healthcare news on November 6, 2026

1. 0108:58 UTC

   FIGS revenue rises 25.7% as demand outruns supply, CEO says

   3 outlets · first: Motley Fool Market trends

   Machine summary FIGS reported Q3 2026 net revenue of $190.7 million, up 25.7% year over year, with CEO Trina Spear telling Bloomberg that demand outstripped supply.

   1. FIGS said that for Q3 2026 its net revenue reached $190.7 million, a 25.7% year-over-year increase, which the company attributed to growth in orders alongside a rise in average order value (company, Nov. 5, 2026 call).
   2. International net revenue rose 51.4% to $36.8 million and is approaching 20% of total business mix; U.S. net revenue grew 20.8% to $153.9 million (company)
   3. Net revenue per active customer reached a company record of $236, up 12.9%; active customers totaled 3.2 million, up 14.3% (company)
   4. Adjusted EBITDA margin was 16.5%, up 410 basis points year over year; diluted EPS was $0.10 versus $0.05 a year earlier (company)
   5. The company reported inventory dropping 20% versus the prior year, ending at $121.3 million, amid a move away from a Jordanian supplier toward Southeast Asian facilities.

   Reported by Bloomberg and Motley Fool.

   • Bloomberg
   • Figs

2. 0216:58 UTC

   Novartis reports nine tumors in children treated with Zolgensma

   2 outlets · first: GEN Regulation

   Machine summary Novartis told MedPage Today it has received nine reports of tumors in children previously treated with its SMA gene therapy Zolgensma since the product's 2019 approval, with two cases showing vector DNA integration. The company said both patients were treated and continue to be monitored, and that health authorities were notified in each case.

   1. Novartis said it has received nine reports of tumors in children previously treated with Zolgensma since the therapy's first approval in 2019, according to a spokesperson's email to MedPage Today.
   2. Zolgensma (onasemnogene abeparvovec), an AAV vector-based gene therapy approved in 2019 for patients under 2 years old with SMA and bi-allelic SMN1 mutations, carries labeling that notes a theoretical risk of tumorigenicity from AAV vector DNA integration into the genome.
   3. According to MedPage Today, a Novartis spokesperson declined to disclose the timing of tumor development and identification in the remaining seven cases.

   Reported by GEN and MedPage Today.

   • Novartis
   • AAV vector
   • Zolgensma
   • onasemnogene abeparvovec

3. 0312:18 UTC

   Hospital courier robots maker Ottonomy raises about Rs 40 crore

   2 outlets · first: Indian Startup News Health IT

   Machine summary Ottonomy, whose Ottobot robots reportedly transport blood samples and supplies along hospital corridors, raised about Rs 40.6 crore ($4.2 million) in a post-seed round led by Enrission India Capital. The company said the capital will support expansion in healthcare and industrial automation, and Enrission principal Harsh Deodhar said skilled hospital staff spend too much of their time moving supplies instead of treating patients.

   1. Japan-based venture firm Enrission India Capital led the round through its Enrission SP26 India fund, the firm said in an announcement
   2. The company said the capital will fund global expansion across healthcare and industrial automation
   3. Founded in 2020 by Ritukar Vijay, Hardik Sharma, Pradyot Korupolu and Ashish Gupta; headquartered in California with more than 60 employees, most in Delhi NCR, and a production facility in Noida
   4. Ottobot travels corridors, calls elevators through an API link with lift controls and passes access-controlled doors, using camera recognition, ultrasonic sensors and edge computing where GPS does not reach
   5. Ottobots first ran commercially at Cincinnati/Northern Kentucky International Airport carrying food and travel essentials before the company shifted focus to hospitals

   Reported by Indian Startup News.

   • Enrission India Capital
   • Ottonomy
   • Enrission SP26 India
   • Cincinnati/Northern Kentucky International Airport
   • Ottobot

4. 0415:25 UTC

   RenovoRx reports 26 active cancer centers as quarterly revenue reaches $1.07M

   2 outlets · first: Seeking Alpha Medical devices

   Machine summary RenovoRx said commercially active cancer centers reached 26 as of Sept. 30, 2026, up from 21 at the end of the second quarter, with a commercial funnel of 65 centers including more than 40 in evaluation or approval. Third-quarter 2026 revenue was $1.07 million, up 17% sequentially, and management kept full-year 2026 guidance at $3.75 million to $4.25 million while describing a target of 36 active centers.

   1. Q3 2026 revenue was $1.07 million, up 17% from Q2 2026 and about four times the year-earlier quarter, the company said on its Nov. 5, 2026 call
   2. Management maintained full-year 2026 revenue guidance of $3.75 million to $4.25 million; Seeking Alpha reported the company is targeting 36 active cancer centers
   3. Commercially active cancer centers totaled 26 as of Sept. 30, 2026, up from 21 at the end of Q2 2026, with a commercial funnel of 65 centers
   4. Gross margin came in at 82% and adjusted gross margin at 85%, according to the company, which said three devices went to a commercial customer from a clinical trial site at zero margin.
   5. Net loss was $3.6 million, or $0.08 per share, versus $2.9 million in Q3 2025; R&D fell to $1.2 million after Phase III trial enrollment completion while SG&A rose to $2.9 million

   Reported by Seeking Alpha and Motley Fool.

   • Phase III trial
   • RenovoRx

5. 0516:25 UTC

   AirSculpt cuts 2026 outlook as procedure volume falls 9.6%

   2 outlets · first: Seeking Alpha Market trends

   Machine summary The company said 250 GLP-1-related cases made up close to 10% of case volume and lowered its full-year 2026 guidance to $144-146 million in revenue and $9-10 million in adjusted EBITDA.

   1. 2,483 procedures were performed, a 9.6% decline on a same-center basis; same-center revenue fell about 7.5% excluding the closed London facility
   2. GLP-1-related cases totaled 250, close to 10% of the quarter's total case volume, the company said
   3. Customer acquisition cost rose to about $3,800 per case from $3,100 a year earlier, with Google search leads down 16% and cost per lead up 26%
   4. Cash was $15.2 million at September 30, 2026; a new $44 million facility ($39 million term loan, $5 million revolver, maturing 2031) priced at SOFR plus 775 basis points
   5. Full-year 2026 guidance was cut to $144-146 million revenue and $9-10 million adjusted EBITDA, from a prior revenue range of $151-157 million

   Reported by Seeking Alpha and Motley Fool.

   • Google
   • SOFR

Each summary and its key facts are a machine summary of the reports linked under it; the outlets, times and counts come from those reports' own records. How a rundown is built.